ARIA, Iclusig launch is tracking above expectations to beat Q2 with potential for EGFR data at ESMO (expectations are rightfully low here given too short of follow-up time on first tumor scan) and 1st line EPIC data in Q3:14. Either EGFR responses or clean safety/efficacy in EPIC could significantly improve ARIA takeout prospects since the company is unencumbered by any partnerships